AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

1.-14. (Canceled)

15. (Original) A method of increasing the oral bioavailability of glycopyrrolate to a patient receiving glycopyrrolate therapy comprising administering to the patient a pharmaceutical tablet comprising about 1 mg to about 10 mg of glycopyrrolate under fasted conditions, wherein the administration results in an increase of the maximum plasma concentration (C_{max}) and the extent of absorption of glycopyrrolate at t = 24 hours ($AUC_{0\text{-}24hrs}$) as compared to the administration of glycopyrrolate under fed conditions.

16. (Original) The method of claim 15 wherein the ratio of C_{max} following administration without food to C_{max} following administration with food is greater than about 1.1, and wherein the ratio of $AUC_{0\text{-}24hrs}$ following administration without food to $AUC_{0\text{-}24hrs}$ following administration with food is greater than about 1.8.

17. (Original) The method of claim 16 wherein the ratio of C_{max} following administration without food to C_{max} following administration with food is greater than about 2.8, and wherein the ratio of $AUC_{0\text{-}24hrs}$ following administration without food to $AUC_{0\text{-}24hrs}$ following administration with food is greater than about 4.5.

18. (Original) The method of claim 16, further comprising informing the patient that the administration of the glycopyrrolate dose in a pharmaceutical composition under fasted conditions results in an increase of the maximum plasma concentration (C_{max}) and the extent of absorption of glycopyrrolate at t = 24 hours ($AUC_{0\text{-}24hrs}$) as compared to the administration of glycopyrrolate under fed conditions.

19. (Original) The method of claim 18, wherein the pharmaceutical composition is provided to a patient in a container associated with prescribing information that advises the patient that the administration of the glycopyrrolate dose in a pharmaceutical composition under fasted conditions results in an increase of the maximum plasma concentration (C_{max}) and the extent of absorption of glycopyrrolate at t = 24 hours ($AUC_{0\text{-}24hrs}$) as compared to the administration of glycopyrrolate under fed conditions.

20-29. (Canceled)